Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The associated price target remains the same with $77.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Capricor Therapeutics’ promising developments. The company has recently reported strong financial results, ending the quarter with $144.8 million in cash, which is expected to support operations through 2027. This financial stability is crucial as Capricor prepares for the upcoming PDUFA date for its groundbreaking cell therapy, deramiocel, aimed at treating Duchenne muscular dystrophy cardiomyopathy.
Additionally, the FDA’s mid-cycle review of deramiocel’s BLA identified no significant deficiencies, keeping the approval process on track for the August 31, 2025, PDUFA date. The anticipated advisory committee (AdCom) meeting presents an opportunity for Capricor to highlight deramiocel’s safety and efficacy, addressing the high unmet need in the DMD space. Pantginis believes that the AdCom could positively influence Capricor’s position, as it allows the company to directly communicate the therapy’s benefits to patients, physicians, and investors, potentially alleviating any remaining concerns and reinforcing deramiocel’s standing as a novel and effective treatment option.